An important article by Bolla et al. has been published in the New England Journal of Medicine today, together with editorial comment by Albertsen. We advise readers to study this article in conjunction with a second article published today under the heading “Hormone therapy and radiation treatment: a topical update.” … READ MORE …
Filed under: Management, Treatment | Tagged: adjuvant, hormone, locally advanced, radiation, therapy | Leave a comment »
There are three reports in our first daily report for 2009, dealing with issues as varied as genetic profiling for prostate cancer risk, the relative merits of LRP and RALP, and the management of geriatric prostate cancer patients who are on long-term hormone therapy. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: gene, geriatric, hormone, LRP, RALP, risk, SNPs | 10 Comments »
In today’s reports:
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: acupuncture, cancer, hormone, news, prostate, testosterone, therapy, update, zoledronic acid | Leave a comment »
For those who are interested in following the abiraterone story in more detail, Bernie Boyce has started a blog on his experiences in enrolling in and (he hopes) participating in the Phase III clinical trial of abiraterone under the supervision of Dr. de Bono at the Royal Marsden Hospital in the UK.
Filed under: Drugs in development, Management, Treatment | Tagged: abiraterone, Add new tag, cancer, hormone, prostate, refractory | 3 Comments »
In today’s prostate cancer news:
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: cancer, cognitive function, hormone, hormone refractory, prostate, satraplatin, therapy | Leave a comment »
Here’s a link to an excellent article on the “real” abiraterone story, written by journalist Robert Sandall, who has advanced prostate cancer himself. He has spoken to researcher Johann de Bono directly, and quotes him as follows:
Some parts of the press have hyped this drug way beyond what I said about it. … This is not a cure, let me correct that. I believe this drug definitely works — but it works much better with some patients than it does with others.
The “New” Prostate Cancer InfoLink is pleased to see Dr. de Bono confirm our earlier analysis of the situation.
Filed under: Drugs in development, Management, Treatment | Tagged: abiraterone, cancer, hormone, prostate, refractory | 4 Comments »
In additional news breaking today:
Filed under: Drugs in development, Management, Treatment | Tagged: cancer vaccine, Dendreon, ED, erectile dysfunction, hormone, NexMed, prostate, Provenge, refractory | Leave a comment »
A paper published today in the Journal of Clinical Oncology suggests that a new agent has been identified for the treatment of end-stage prostate cancer. The paper is being quoted in the media and is likely to reinvigorate discussion about the merits and risks of agents targeting hormone synthetic pathways. Continue reading
Filed under: Drugs in development, Management, Treatment | Tagged: abiraterone, cancer, deprivation, flutamide, hormone, prostate, PSA | 10 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 